Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10150432 | 0.85 | CRHR1 (0.36) | CRHR1HPGDNPSR1MCOLN3SMN1; SMN2 | |
| SCHEMBL10150593 | 0.85 | CRHR1 (0.36) | CRHR1HPGDNPSR1MCOLN3SMN1; SMN2 | |
| SCHEMBL12142624 | 0.85 | CRHR1 (0.36) | CRHR1HPGDNPSR1MCOLN3SMN1; SMN2 | |
| SCHEMBL10150613 | 0.82 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL10150637 | 0.81 | — | — | |
| SCHEMBL10150434 | 0.77 | CYP3A4 (0.40) | CRHR1HPGDSMN1; SMN2POLBALDH1A1 | |
| SCHEMBL10150588 | 0.77 | PRKCA (0.39) | CRHR1HPGDSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL14293726 | 0.76 | HSP90AA1 (0.32) | — | |
| SCHEMBL10150585 | 0.75 | CYP2C19 (0.43) | CRHR1SMN1; SMN2ALDH1A1MEN1LMNA | |
| SCHEMBL10150653 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450305-B2 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2013-05-28 | — | — | US | disclosed |
| US-20120077775-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-03-29 | — | — | US | disclosed |
| US-8067412-B2 | analogs of natural products radicicol and pochonins; (oxirane or cyclopropan) 2-benzoxacyclo(di)tetradecin derivatives; inhibition of kinase phosphorylation activity and heat shock proteins; anticarcinogenic, antiinflammatory agent; neurodegenerative diseases; antiallergen | UNIVERSITE DE STRASBOURG (FR) | 2011-11-29 | — | — | US | disclosed |
| US-20100292218-A1 | Treatment Of Neurofibromatosis With Radicicol And Its Derivatives | NEXGENIX PHARMACEUTICALS HOLDINGS, INC. | 2010-11-18 | — | — | US | disclosed |
| US-20080146545-A1 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077775-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | HSP90AB1, HSP90AA1, HSP90AB2P | CRHR1 1638/4885HPGD 1308/4885NPSR1 3022/4885 |
| US-20100292218-A1 | Treatment Of Neurofibromatosis With Radicicol And Its Derivatives | HSP90AB2P, HSP90AA1, HSPA2 | CRHR1 2595/4885HPGD 911/4885NPSR1 3953/4885 |
| US-20080146545-A1 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | HSP90AB1, HSP90AA1, HSP90AB2P | CRHR1 1638/4885HPGD 1308/4885NPSR1 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.